SECTOR : Biotech
ENTRY DATE : 2009
EXIT DATE : 2017
BUSINESS : Venture Capital
WEB : www.argenx.com

arGEN-X

A new antibody platform targeting the treatment of cancer and autoimmune conditions

arGEN-X is a research-stage biopharmaceutical company with a broadly applicable, proprietary platform called SIMPLE Antibody™. Using this platform, arGEN-X is able to create a wide range of monoclonal antibody leads against a broad range of human disease targets. These antibodies are then given highly competitive properties using other technologies in many cases. The company has proven the benefits of its monoclonal antibody development platform by signing numerous partnerships and pursuing two proprietary clinical programmes.

PRESS RELEASE(S) :

03/12/2009• Crédit Agricole Private Equity takes a stake in arGEN-X
Lire

09/06/2014• Successful IPO for arGEN-X, a Dutch biopharmaceuticals company supported by Omnes Capital since 2009
Lire